Showing 1,801 - 1,820 results of 18,308 for search 'significant ((((step decrease) OR (((mean decrease) OR (nn decrease))))) OR (a decrease))', query time: 0.71s Refine Results
  1. 1801
  2. 1802
  3. 1803
  4. 1804
  5. 1805
  6. 1806
  7. 1807

    Changes in alpha diversity in the weeks before anti-TNF-a treatment. by Katrine Carlsen (5477300)

    Published 2024
    “…The analysis found a significant association across all subjects for Shannon diversity with decreasing diversity in the lead up to the next treatment (lmer model, beta = -0.018, <i>p</i> = 0.036) and no association for observed diversity (<i>p</i>>0.1). …”
  8. 1808
  9. 1809
  10. 1810
  11. 1811
  12. 1812

    Supplementary Material for: Effect of Surface Perturbation Treadmill Training Program on Strategies and Kinematics of Reactive Stepping during Standing in Older Adults: A Single-Bl... by figshare admin karger (2628495)

    Published 2025
    “…Fall incidents were monitored prospectively one year after training for a secondary outcome. Results: Both groups showed a significant decrease in the percentage of multiple-step responses (p=0.013) and a shorter total recovery time to recover balance (p=0.006). …”
  13. 1813
  14. 1814
  15. 1815
  16. 1816
  17. 1817
  18. 1818

    Presentation 1_Decreased brain-derived neurotrophic factor expression in chronic kidney disease: integrated clinical and experimental evidence.pptx by Juan Chen (61123)

    Published 2025
    “…</p>Conclusion<p>This study integrated meta-analysis, murine model validation, and single-cell transcriptomic profiling to demonstrate a significant reduction of BDNF in CKD. Furthermore, renal BDNF expression decreased locally, predominantly originating from proximal tubule cells, macrophages, and podocytes, possibly epigenetically inhibited by the upregulation of lnc RNA Bdnf-as.…”
  19. 1819

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  20. 1820

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”